A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.

A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Cancer. 2016 Nov 15; 122(21):3327-3335.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Bortezomib
Dexamethasone
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Female
Follow-Up Studies
Humans
Male
Maximum Tolerated Dose
Middle Aged
Multiple Myeloma
Neoplasm Recurrence, Local
Neoplasm Staging
Prognosis
Salvage Therapy
Thiadiazoles

authors with profiles

Andrzej Jakubowiak